Key Points
- Director Raymond Anderson sold 3,142 Monopar shares at an average price of $68.35, for proceeds of about $214,756. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- After the sale, Anderson held 5,373 shares, valued at approximately $367,245; his reported ownership decreased by 36.9%. He had also sold 3,142 shares in August at an average price of $111.77.
- Analysts’ consensus rating was Moderate Buy, with a consensus price target of $122. The stock opened at $72.81, within a reported 52-week range of $50.07 to $124.82.
Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) Director Kim Tsuchimoto sold 1,199 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $70.10, for a total transaction of $84,049.90. Following the completion of the sale, the director owned 1,199 shares of the company's stock, valued at approximately $84,049.90. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Monopar Therapeutics Stock Performance
Shares of NASDAQ MNPR opened at $72.81 on Thursday. The firm has a market capitalization of $488.56 million, a P/E ratio of -33.55 and a beta of 1.62. Monopar Therapeutics Inc. has a one year low of $50.07 and a one year high of $124.82. The company's fifty day moving average is $88.66 and its two-hundred day moving average is $77.40.
Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, sell-side analysts forecast that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of research analysts have weighed in on MNPR shares. Morgan Stanley reissued an "overweight" rating and set a $130.00 price target on shares of Monopar Therapeutics in a research note on Monday, August 17th. UBS Group set a $125.00 price objective on Monopar Therapeutics in a research report on Thursday, July 23rd. Cantor Fitzgerald lowered Monopar Therapeutics from an "overweight" rating to a "neutral" rating and upped their target price for the company from $109.00 to $119.00 in a research note on Thursday, August 13th. Barclays reiterated an "overweight" rating and set a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a research report on Friday, September 11th. Finally, Zacks Research lowered Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Monopar Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $122.00.
Check Out Our Latest Research Report on MNPR
Trending Headlines about Monopar Therapeutics
Here are the key news stories impacting Monopar Therapeutics this week:
- Neutral Sentiment: Monopar is projected to announce quarterly earnings on Thursday. The report could give investors an update on the company’s performance; no results or estimates are detailed in the article. Monopar Therapeutics projected to announce quarterly earnings
- Neutral Sentiment: A separate article raises the question of what investment firms think about MNPR, but the provided information does not specify any firms’ ratings, price targets, or recent actions. What investment firms are thinking about MNPR
- Negative Sentiment: Directors reported selling shares: Kim Tsuchimoto sold 2,891 shares on Nov. 4 and 1,199 on Nov. 2, while Raymond Anderson sold 3,142 shares on Nov. 2. The sales reduced their reported holdings and could concern investors, although the transactions were made under pre-arranged Rule 10b5-1 plans. SEC filing for director transactions
Hedge Funds Weigh In On Monopar Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Siren L.L.C. boosted its position in shares of Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company's stock worth $14,800,000 after buying an additional 57,820 shares during the period. ADAR1 Capital Management LLC grew its stake in shares of Monopar Therapeutics by 13.0% in the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock valued at $14,480,000 after buying an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Monopar Therapeutics in the second quarter valued at about $7,124,000. Walleye Capital LLC purchased a new stake in shares of Monopar Therapeutics during the 1st quarter valued at about $3,458,000. Finally, Bank of America Corp DE raised its holdings in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company's stock valued at $3,271,000 after buying an additional 53,336 shares during the period. Institutional investors and hedge funds own 1.83% of the company's stock.
Monopar Therapeutics Company Profile
(
Get Free Report)
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing investigational therapies for cancer. The company's research programs are centered on radiopharmaceuticals and oncology treatments intended to improve the diagnosis and treatment of serious malignancies.
Monopar's pipeline includes MNPR-101-Zr, a zirconium-89-labeled antibody fragment being developed as a positron emission tomography imaging agent targeting the urokinase plasminogen activator receptor, or uPAR.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
